| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Orion Oyj: Orion Corporation completed share acquisitions | 2 | GlobeNewswire (USA) | ||
| 04.09. | Orion Oyj: 102,000 Orion Corporation A shares converted into B shares | 3 | GlobeNewswire (USA) | ||
| 14.08. | ORION Corp. Reports Higher Revenue And Profit In Q2 2026 | 813 | AFX News | SEOUL (dpa-AFX) - ORION Corp. (271560.KS) on Friday reported revenue of KRW 893.59 billion for the second quarter of 2026, compared with KRW 777.17 billion in the same period of 2025. For the... ► Artikel lesen | |
| 10.08. | Orion Oyj: Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint | 811 | GlobeNewswire (Europe) | ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary... ► Artikel lesen | |
| 17.07. | ROUNDUP: Orion Q2 Profit Rises; Revises Outlook | 627 | AFX News | HELSINKI (dpa-AFX) - (Adds Outlook)For the full year, Orion Oyj (0M2N.L) now expects operating profit of EUR 650 million to EUR 750 million, compared with the previous expectation of EUR 600... ► Artikel lesen | |
| ORION OYJ A Aktie jetzt für 0€ handeln | |||||
| 17.07. | Orion Oyj Reveals Advance In Q2 Income | 643 | AFX News | HELSINKI (dpa-AFX) - Orion Oyj (0M2N.L) reported earnings for its second quarter that Increased, from last yearThe company's bottom line came in at EUR140.2 million, or EUR1 per share. This... ► Artikel lesen | |
| 17.07. | Orion Oyj: Orion Group Half-Year Financial Report January-June 2026 | 914 | GlobeNewswire (Europe) | ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1-6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January-June 2026 April-June 2026 Highlights Net sales totalled EUR 521.6... ► Artikel lesen | |
| 17.07. | Orion Oyj: Orion Corporation's financial reporting and Annual General Meeting in 2027 | 4 | GlobeNewswire (USA) | ||
| 15.07. | Orion Oyj: 45,611 Orion Corporation A shares converted into B shares | 4 | GlobeNewswire (USA) | ||
| 06.07. | Shilpa Medicare Limited: Orion und Shilpa Medicare bauen Partnerschaft aus, um Nivolumab Biosimilar für Europa zu entwickeln und zu liefern | 710 | Business Wire | Shilpa Medicare Limited gab bekannt, dass seine hundertprozentige Tochtergesellschaft, Shilpa Biologicals Private Limited, mit der Orion Corporation eine Vereinbarung über die gemeinsame Entwicklung... ► Artikel lesen | |
| 06.07. | Shilpa Medicare Limited: Orion Corporation and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe | 755 | Business Wire | Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous... ► Artikel lesen | |
| 03.07. | Orion Oyj: Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026 | 4 | GlobeNewswire (USA) | ||
| 30.06. | Shilpa Medicare jumps as subsidiary signs biosimilar pact with Finland's Orion | 3 | capitalmarket.com | ||
| 30.06. | Orion Oyj: Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market | 891 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 30 JUNE 2026 at 8.00 EEST Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market Orion Pharma ("Orion") and Shilpa... ► Artikel lesen | |
| 26.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 26.06.2026 | 578 | Xetra Newsboard | The following instruments on XETRA do have their first trading 26.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.06.2026
Aktien
1 CNE100007NS5 Keytop Parking Inc.
2... ► Artikel lesen | |
| 23.06. | Orion Oyj: Orion Pharma's ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission | 706 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma's ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission Orion Corporation... ► Artikel lesen | |
| 15.06. | Orion Oyj: Disclosure Under Chapter 9 Section 10 of the Securities Market Act | 5 | GlobeNewswire (USA) | ||
| 10.06. | Orion Oyj: Disclosure Under Chapter 9 Section 10 of the Securities Market Act | 3 | GlobeNewswire (USA) | ||
| 05.06. | Orion Oyj: Disclosure Under Chapter 9 Section 10 of the Securities Market Act | 2 | GlobeNewswire (USA) | ||
| 30.05. | Orion Oyj: Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours | 471 | GlobeNewswire (Europe) | ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ELI LILLY | 1.019,20 | +0,33 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| INCYTE | 102,25 | -0,20 % | Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals und Incyte melden FDA-Zulassung für Atebrioz (Zilurgisertib) für erwachsene und pädiatrische Patienten mit Fibrodysplasia ossificans progressiva | - Einmal täglich oral verabreichter ALK2-Hemmer erhält Zulassung zur Reduzierung des Volumens der gesamten neuen heterotopischen Verknöcherung bei Patienten mit FOP im Alter von über 12 Jahren ... ► Artikel lesen | |
| BACHEM | 85,20 | -0,12 % | EQS-News: Claros Technologies gibt die weitere geschäftliche Expansion nach Europa sowie den Einstieg in die pharmazeutische Produktion bekannt - nach einem erfolgreichen Pilotprojekt zur PFAS-Zerstörung bei der Bachem AG | EQS-News: Claros Technologies
/ Schlagwort(e): ESG/Expansion
Claros Technologies gibt die weitere geschäftliche Expansion nach Europa sowie den Einstieg in die pharmazeutische... ► Artikel lesen | |
| WUXI BIOLOGICS | 6,110 | -0,65 % | HSI Closes at 24,613, Up 89 pts; HSTI Closes at 4,253, Up 4 pts; CSPC PHARMA Up over 6%; WUXI BIO, WUXI APPTEC, GENSCRIPT BIO, H&H INTL HLDG Hit New Highs; Market Turnover Rises | ||
| DAIICHI SANKYO | 15,650 | +0,64 % | Warum AstraZeneca, Pfizer und NurExone die Wirkstoffabgabe als Teil des Arzneimitteldesigns verstehen | ||
| UCB | 202,50 | -1,51 % | UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS) | Antiphospholipid syndrome (APS) is a serious autoimmune condition that mainly affects women of childbearing age (WoCBA) and can cause serious adverse pregnancy... ► Artikel lesen | |
| ASTELLAS PHARMA | 13,000 | +0,78 % | Dividendenbekanntmachungen (29.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 52 JPY 0,2906 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1799 EUR ACOM CO LTD JP3108600002 11 JPY 0... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| ORION | 81,05 | -0,12 % | Orion Oyj: Orion Corporation completed share acquisitions | ||
| AURINIA PHARMACEUTICALS | 14,115 | +0,36 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| GALDERMA GROUP | 172,50 | -0,14 % | Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitis | WASHINGTON (dpa-AFX) - Galderma (GALD) reported new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements... ► Artikel lesen | |
| AMPHASTAR | 22,450 | 0,00 % | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 |
Net revenues of $183.9 million for the three months ended June 30, 2026
GAAP net income of $30.3 million, or $0.67 per share, for the second quarter
Adjusted... ► Artikel lesen | |
| HANSOH PHARMACEUTICAL | 3,870 | +0,13 % | EQS-News: Hansoh Pharma: 19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt | EQS-News: Hansoh Pharma
/ Schlagwort(e): Sonstiges
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten,... ► Artikel lesen | |
| LIFEVANTAGE | 5,250 | +0,96 % | Dividendenbekanntmachungen (01.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,42 USD 0,3614 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,2 USD 0,1721 EUR AGNICO EAGLE MINES... ► Artikel lesen | |
| PHARMANUTRA | 70,10 | -2,64 % | Dividendenbekanntmachungen (04.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,1212 USD 0,1034 EUR AGRICULTURAL BANK OF CHINA LTD CNE100000Q43 0,13 CNY 0,0162 EUR ALERION CLEANPOWER... ► Artikel lesen |